Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 927 of 5804
-
New drug aims to stop relapses in rare brain disease
Disease control TerminatedThe purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Neuromyelitis Optica Spectrum Disorders.
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Gene therapy trial for duchenne MD halted early – what we know
Disease control TerminatedThis is a first-in-human/first-in-patient, multi-center, open-label, non-randomized, ascending dose, safety and tolerability study of a single intravenous infusion of PF-06939926 in ambulatory and non-ambulatory subjects with Duchenne muscular dystrophy (DMD). Other objectives in…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 26, 2026 17:12 UTC
-
Could stem cells slow Huntington's? new trial tests cellavita HD
Disease control CompletedCellavita HD is a stem-cell therapy for Huntington's Disease. This is a prospective, phase II, single-center, randomized (2:2:1), triple-blind, placebo controlled study, with two test doses of Cellavita HD product.
Phase: PHASE2 • Sponsor: Azidus Brasil • Aim: Disease control
Last updated Jun 26, 2026 18:55 UTC
-
Laser rejuvenation may shield aging skin from cancer
Disease control Recruiting nowThis study is following up on previous studies that have demonstrated that geriatric subjects respond different to ultraviolet B (UVB) light than young subjects. The treatment of geriatric skin with dermal rejuvenation therapies (dermabrasion, fractionated laser resurfacing) rest…
Phase: NA • Sponsor: Wright State University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New combo therapy targets tough brain tumors
Disease control CompletedThe purpose of this Phase 2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in combination with a standard of care radiation regimen when used to treat newly diagnosed GBM in patients with unmethylated promoter of the methy…
Phase: PHASE2 • Sponsor: Kintara Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:06 UTC
-
Bionic hand that 'feels' moves closer to reality in small trial
Disease control OngoingThis study is designed to evaluate the feasibility of The Adaptive Neural Systems Neural-Enabled Prosthetic Hand (ANS-NEPH) system.
Phase: NA • Sponsor: University of Arkansas, Fayetteville • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New melphalan combo shows promise in Half-Matched transplants for blood cancer patients
Disease control CompletedThis is an open-label, single-arm, phase II study to determine the safety of propylene glycol-free melphalan HCl (EVOMELA®), in combination with fludarabine and total-body irradiation-based reduced-intensity conditioning for haploidentical transplantation. In addition, the study …
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill could replace hormone shots for prostate cancer
Disease control OngoingThis is an open label non-comparative controlled randomized phase II study. The experimental arm is the group receiving ODM-201. The group receiving androgen-deprivation therapy (ADT) is included as an internal control. The primary trial objective is to demonstrate that ODM-201 …
Phase: PHASE2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 26, 2026 19:06 UTC
-
Brain pacemaker tested in older Parkinson's patients
Disease control CompletedDeep brain stimulation of the sub thalamic nucleus (STN-DBS) is an efficient treatment to improve motor and non motor signs of Parkinson's disease (PD). In people aged more 70 years, an increased rate of side effects such as post-operative cognitive decline and/or postural instab…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: targeted pill aims to stop tumor growth
Disease control Recruiting nowThis research study is studying a targeted therapy as a possible treatment for cancer abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6. The drug involved in this study is: -Abemaciclib
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis phase II Pediatric MATCH trial studies how well tazemetostat works in treating patients with brain tumors, solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have come back (relapsed) or do not respond to treatment (refractory) and have EZH2, SMARCB1, or SMARC…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Pill could replace needles for Kidney-Related anemia
Disease control CompletedFor Non-dialysis subjects with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548. For subjects not currently receiving ESAs, evaluate Hb correction and mainte…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could just 5 radiation sessions be as good as 15 for breast cancer?
Disease control CompletedAdjuvant radiotherapy after breast-conserving surgery for breast cancer reduces the risk of locoregional relapse and ensures better overall survival. In recent years it has been found that hypofractionation in which the number of radiation sessions is reduced with a higher dose p…
Phase: NA • Sponsor: University Hospital, Ghent • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New dissolving stent could improve heart artery treatment
Disease control CompletedThe primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the XIENCE or Promus durable polymer coronary stents. This prospective, global, multi-center, ra…
Phase: NA • Sponsor: Sino Medical Sciences Technology Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for kids with pompe disease: experimental drug shows promise
Disease control OngoingThis is a multi-stage, phase 2, open-label, multicenter, multinational, ascending dose cohort, repeated intravenous (IV) infusion study of avalglucosidase alfa in pediatric patients with Infantile-Onset Pompe Disease (IOPD) who have been previously treated with alglucosidase alfa…
Phase: PHASE2 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Smart water bottle trial aims to flush away kidney stones
Prevention CompletedA randomized clinical trial to investigate the impact of increased fluid intake and increased urine output on the recurrence rate of urinary stone disease (USD) in adults and children. The primary aim of the trial is to determine whether a multi-component program of behavioral in…
Phase: NA • Sponsor: Duke University • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
New cocktail aims to tackle tough leukemia
Disease control CompletedBackground: Chronic lymphocytic leukemia and small lymphocytic lymphoma (hereby referred as CLL) are tumors of B cells. A subset of patients categorized as high-risk CLL has a poor clinical outcome when treated with conventional chemotherapy. This single-arm, phase II study inve…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Rare baby diabetes study could rewrite treatment rules
Knowledge-focused Recruiting nowType 1 diabetes (T1D) results from destruction of insulin-producing beta cells in the pancreas by the body's own immune system (autoimmunity). It is not fully understood what causes this type of diabetes and why there is variation in age of onset and severity between people who d…
Sponsor: University of Exeter • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Should you zap or wait? new trial tackles meningioma dilemma
Disease control Recruiting nowThis randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink t…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo therapy shows promise for Hard-to-Treat breast cancer on chest wall
Disease control CompletedThis is a phase II multicenter study including breast cancer patients with chest wall disease that is hormone resistant (estrogen receptor (ER) positive/progesterone receptor (PR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer with progressive dis…
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC